Prochelator strategies for site-selective activation of metal chelators.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Inorganic Biochemistry

• Publication date

  2016-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jinorgbio.2016.05.012PMID 27297691
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases.

  2016cited by this paper
• A multifunctional, light-activated prochelator inhibits UVA-induced oxidative stress.

  2015cited by this paper
• New Glycoconjugates for the Treatment of Diseases Related to Metal Dyshomeostasis

  2015cited by this paper
• Thioflavin-based molecular probes for application in Alzheimer's disease: from in silico to in vitro models.

  2015cited by this paper
• A prochelator peptide designed to use heterometallic cooperativity to enhance metal ion affinity† †Electronic supplementary information (ESI) available: Experimental procedures and Fig. S1–S9 showing plots of lifetime, absorbance, titration, HPLC and mass spectra. See DOI: 10.1039/c5sc00602c

  2015cited by this paper
• New 8-hydroxyquinoline galactosides. The role of the sugar in the antiproliferative activity of copper(II) ionophores.

  2015cited by this paper
• Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.

  2014cited by this paper
• Exploiting innate immune cell activation of a copper-dependent antimicrobial agent during infection.

  2014cited by this paper
• A prochelator with a modular masking group featuring hydrogen peroxide activation with concurrent fluorescent reporting.

  2014cited by this paper
• Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators.

  2014cited by this paper
• Glycosylated copper(II) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy.

  2013cited by this paper
• Glucose conjugation for the specific targeting and treatment of cancer.

  2013cited by this paper
• Disulfide/thiol switches in thiosemicarbazone ligands for redox-directed iron chelation.

  2013cited by this paper
• Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators.

  2012cited by this paper
• Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

  2012cited by this paper
• Oxidative Stress: A Pathogenic Mechanism for Niemann-Pick Type C Disease

  2012cited by this paper
• Increased copper levels in in vitro and in vivo models of Niemann-Pick C disease

  2012cited by this paper
• A boronate prochelator built on a triazole framework for peroxide-triggered tridentate metal binding.

  2012cited by this paper
• A Cell-Permeable Fluorescent Prochelator Responds to Hydrogen Peroxide and Metal Ions by Decreasing Fluorescence.

  2012cited by this paper
• Copper Homeostasis at the Host-Pathogen Interface*

  2012cited by this paper
• Gluconjugates of 8-hydroxyquinolines as potential anti-cancer prodrugs.

  2012cited by this paper
• Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation.

  2012cited by this paper
• Evaluation of a DTPA Prodrug, C2E5 as an Orally Bioavailable Radionuclide Decorporation Agent

  2012cited by this paper
• A sulfur tripod glycoconjugate that releases a high-affinity copper chelator in hepatocytes.

  2012cited by this paper
• D-galactose as a vector for prodrug design.

  2011cited by this paper
• Prochelators triggered by hydrogen peroxide provide hexadentate iron coordination to impede oxidative stress.

  2011cited by this paper
• Hepatocyte targeting and intracellular copper chelation by a thiol-containing glycocyclopeptide.

  2011cited by this paper
• Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.

  2011cited by this paper
• Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxide

  2010cited by this paper
• Toward the development of prochelators as fluorescent probes of copper-mediated oxidative stress.

  2010cited by this paper
• In vitro studies of 3-hydroxy-4-pyridinones and their glycosylated derivatives as potential agents for Alzheimer's disease.

  2010cited by this paper
• Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer’s Disease

  2010cited by this paper
• Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

  2010cited by this paper
• A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation.

  2010cited by this paper
• Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.

  2010cited by this paper
• Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease.

  2010cited by this paper
• Hydrogen peroxide activated matrix metalloproteinase inhibitors: a prodrug approach.

  2010cited by this paper
• A novel H2O2-triggered anti-Fenton fluorescent pro-chelator excitable with visible light.

  2009cited by this paper
• Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps.

  2009cited by this paper
• Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

  2009cited by this paper
• Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer's therapy.

  2009cited by this paper
• A Prochelator Activated by Hydrogen Peroxide Prevents Metal‐Induced Amyloid β Aggregation

  2009cited by this paper
• Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.

  2009cited by this paper
• Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide.

  2008cited by this paper
• Prodrugs: design and clinical applications

  2008cited by this paper
• Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress.

  2007cited by this paper
• Hydrogen peroxide triggered prochelator activation, subsequent metal chelation, and attenuation of the fenton reaction.

  2007cited by this paper
• Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease.

  2006cited by this paper
• Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death.

  2006cited by this paper
• A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation.

  2006cited by this paper
• Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

  2006cited by this paper
• The Design of Orally Active Iron Chelators

  2005cited by this paper
• The design of orally active iron chelators.

  2005cited by this paper
• Wilson Disease

  2005cited by this paper
• Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments.

  2005cited by this paper
• Boronate-based fluorescent probes for imaging cellular hydrogen peroxide.

  2005cited by this paper
• Copper storage diseases: Menkes, Wilsons, and cancer.

  2004cited by this paper
• Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity

  2003cited by this paper
• Regioselective conversion of arylboronic acids to phenols and subsequent coupling to symmetrical diaryl ethers.

  2001cited by this paper
• Practical management of iron overload

  2001cited by this paper
• Increased iron in the dentate nucleus of patients with Friedreich's ataxia

  1999cited by this paper
• In vivo and in vitro effects of boron and boronated compounds.

  1998cited by this paper
• Copper, iron and zinc in Alzheimer's disease senile plaques.

  1998cited by this paper
• Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo.

  1993cited by this paper
• Biologically useful chelators that take up calcium(2+) upon illumination

  1989cited by this paper
• Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.

  1988cited by this paper
• Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy.

  1984cited by this paper
• Electrophilic Displacement Reactions. III. Kinetics of the Reaction between Hydrogen Peroxide and Benzeneboronic Acid1

  1954cited by this paper

• D-Penicillamine/Dihydroquercetin Dual-Loaded Metal–Organic Framework as a Microenvironment Copper Regulator for Enhancing the Therapeutic Efficacy of Polyphenolic Antioxidant in Alzheimer’s Disease

  2025cites this paper
• Advancing anticancer chelation therapy: Insights from enhancing cytotoxic potency, targeted cellular delivery, metal-based immunomodulation, and combinatorial strategies

  2025cites this paper
• Exploring the effect of copper on the bioactivity of 8-quinolines: an in vitro and in vivo study.

  2025cites this paper
• Targeting Bacterial Biofilms on Medical Implants: Current and Emerging Approaches

  2025cites this paper
• Disulfide-based 2-pyridyl-hydrazone prochelators induce iron deprivation and oxidative stress in ovarian cancer cells

  2025cites this paper
• Cu(I) chelators: Useful tools to reveal and control Cu(I) homeostasis and toxicity

  2025cites this paper
• Cuproplasia and cuproptosis in hepatocellular carcinoma: mechanisms, relationship and potential role in tumor microenvironment and treatment

  2025cites this paper
• Bridging the gap between theory and treatment: Transition metal complexes as successful candidates in medicine

  2025cites this paper
• Recent advances in copper homeostasis-involved tumor theranostics

  2024cites this paper
• Cuproptosis and its application in different cancers: an overview

  2023cites this paper
• Design of Tetrazolium Cations for the Release of Antiproliferative Formazan Chelators in Mammalian Cells.

  2023cites this paper
• The Role of Iron Metabolism, Lipid Metabolism, and Redox Homeostasis in Alzheimer’s Disease: from the Perspective of Ferroptosis

  2023cites this paper
• Selective Targeting of Cancer Cells by Copper Ionophores: An Overview

  2022cites this paper
• Thiol-Reactive Arylsulfonate Masks for Phenolate Donors in Antiproliferative Iron Prochelators.

  2022cites this paper
• A Stimuli-Responsive Small-Molecule Metal-Carrying Prochelator: A Novel Prodrug Design Strategy for Metal Complexes.

  2022cites this paper
• Salpyran: A Cu(II) Selective Chelator with Therapeutic Potential.

  2021cites this paper
• Current Research on Pro-Drug Therapies for Parkinson's and Alzheimer's Disease.

  2021cites this paper
• Biomedical applications of copper ionophores

  2020cites this paper
• Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents.

  2020cites this paper
• Carnoquinolines Target Copper Dyshomeostasis, Aberrant Protein-Protein Interactions, and Oxidative Stress.

  2020cites this paper
• Iron and Ferroptosis as Therapeutic Targets in Alzheimer’s Disease

  2020cites this paper
• Prodrug strategies for targeted therapy triggered by reactive oxygen species.

  2019cites this paper
• Iron and manganese-related CNS toxicity: mechanisms, diagnosis and treatment

  2019cites this paper
• Cardioprotective Potential of Iron Chelators and Prochelators.

  2019cites this paper
• Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

  2019cites this paper
• Developing Ligands to Target Transition Metals in Cancer

  2019cites this paper
• Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.

  2019cites this paper
• Metal Ions and Complexes in Alzheimer's Disease: From Fundamental to Therapeutic Perspectives

  2018cites this paper
• Encapsulation of Zn-DTPA into poly lactic-co-glycolic acid nanoparticles via a modified double emulsion method for extended release into lung fluid 1

  2018cites this paper
• University of Dundee Anti-trypanosomal 8-hydroxyl naphthyridines are chelators of divalent transition metals

  2018cites this paper
• Nouveaux peptides chélateurs du Cu(I) comme candidat potentiel pour le traitement de maladie de Wilson

  2018cites this paper
• Positional isomers of mannose–quinoline conjugates and their copper complexes: exploring the biological activity

  2018cites this paper
• New peptidic Cu(I) chelators as potential candidates for the treatment of Wilson’s disease

  2018cites this paper
• Disulfide-masked iron prochelators: Effects on cell death, proliferation, and hemoglobin production.

  2018cites this paper
• Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals

  2018cites this paper
• Modifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress.

  2018cites this paper
• Zinc Complexes of Cyclodextrin-bearing 8-Hydroxyquinoline Ligands: A Comparative Study.

  2017cites this paper
• The hydrolytic susceptibility of prochelator BSIH in aqueous solutions.

  2017cites this paper